Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer

By Critz F.A.   Levinson K.   Williams W.H.   Holladay D.   Holladay C.   Griffin V.  

Urology, Vol. 49, Iss. 5, 1997-05 ,pp. : 668-672

Elsevier

Access to resources Recommend Favorite

Percent free prostate-specific antigen after radiotherapy for prostate cancer - 8 to 10 ng/mL total PSA

By Crook J.M.   Bunting P.S.  

Urology, Vol. 52, Iss. 1, 1998-07 ,pp. : 100-105

Elsevier

Access to resources Recommend Favorite

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml

By Fang J.   Metter E.J.   Landis P.   Carter H.B.  

Urology, Vol. 59, Iss. 6, 2002-06 ,pp. : 889-893

Elsevier

Access to resources Recommend Favorite

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

By Sokoll L.J.   Chan D.W.   Mikolajczyk S.D.   Rittenhouse H.G.   Evans C.L.   Linton H.J.   Mangold L.A.   Mohr P.   Bartsch G.   Klocker H.   Horninger W.   Partin A.W.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 274-276

Elsevier

Access to resources Recommend Favorite

Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL

By Ito K.   Yamamoto T.   Ohi M.   Kurokawa K.   Suzuki K.   Yamanaka H.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 760-764

Elsevier

Access to resources Recommend Favorite